+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are conducting a Phase 3, multicenter, open-label study to evaluate the pharmacokinetics and safety of dupilumab in children and adolescents aged 6 months to under 18 years who have prurigo nodularis. This condition requires participants to have a clinical diagnosis with specific lesion and itch severity criteria to be included. The study aims to better understand how dupilumab behaves in the body and its safety profile in this population. Participants will receive dupilumab administered subcutaneously, with dosing based on their weight and age. The study includes three distinct periods a screening period lasting 2 to 4 weeks, a treatment period of 24 weeks during which dupilumab is given, and a post-intervention follow-up period lasting 16 weeks. The total participation time is approximately 42 to 44 weeks, and there will be six planned study visits for each participant. During the study, participants and caregivers will complete daily symptom e-diaries to track itch severity and other symptoms. Researchers will monitor the concentration of dupilumab in the blood from Day 1 through Week 40, as well as the incidence of any treatment-related adverse events and the development of anti-drug antibodies. Safety and effectiveness will be assessed throughout the treatment and follow-up periods, ensuring thorough observation over the entire study duration.

Age: 6Months - 17YearsAll GendersPhase 3
15 locations
S

Actively Recruiting

The trial investigates the safety and performance of the commercially available PERFORM174 Humeral System for shoulder arthroplasty in patients with conditions such as osteoarthritis, avascular necrosis, post-traumatic arthrosis of the shoulder, and rotator cuff tear arthropathy. This international, prospective, single-arm study collects data to evaluate quality of life, pain, functional improvements, implant safety, and radiographic results over a long follow-up period. Participants receive the Tornier Perform Humeral Stem device for partial or total shoulder replacement. The study involves baseline data collection, surgery, immediate postoperative assessments, and annual follow-ups for up to 10 years. The goal is to monitor patient-reported outcomes and device performance continuously throughout this period. During the study, participants will provide information on their shoulder function and quality of life using established scoring systems like the ASES and Constant Murley scores. Researchers will also evaluate adverse events, revision surgeries, and imaging of the shoulder. Follow-up visits occur regularly from baseline through 10 years post-operation, ensuring ongoing safety and performance monitoring.

Age: 18Years +All Genders
11 locations
C

Actively Recruiting

Researchers are investigating treatment options for people with active rheumatoid arthritis RA who have not responded well to a tumor necrosis factor inhibitor TNFi biologic medication. The study compares two treatment strategies switching to a non-TNFi biologic drug such as rituximab, abatacept, tocilizumab, or sarilumab versus switching to a targeted synthetic disease-modifying antirheumatic drug tsDMARD like tofacitinib, baricitinib, or upadacitinib. This research addresses a significant gap in knowledge as current guidelines recommend switching treatments but lack strong evidence comparing these options directly, especially regarding patient-reported outcomes PROs like function and quality of life. Participants will be randomly assigned to receive either a non-TNFi biologic or a targeted synthetic DMARD. The choice of specific medication within each class is based on what is available and accessible through insurance or patient assistance programs. The study follows a pragmatic design to reflect real-world treatment decisions and includes patients with comorbidities. Treatment continues with stable doses of certain conventional synthetic DMARDs if already being used. This head-to-head trial aims to provide comparative effectiveness data for these two treatment strategies over a 12-month period. During the trial, participants will be monitored for changes in functional limitations using the Health Assessment Questionnaire HAQ, a sensitive tool for measuring outcomes important to patients with RA. Researchers will also track treatment toxicity and quality of life changes. The study involves regular assessments over one year to evaluate the benefits and risks of each treatment approach, helping patients and providers make informed decisions based on outcomes that matter most to patients.

Age: 18Years +All GendersPhase 3
49 locations